دورية أكاديمية
أعرض في EDS

A scoping review of the use of minimally important difference of EQ-5D utility index and EQ-VAS scores in health technology assessment.

التفاصيل البيبلوغرافية
العنوان: A scoping review of the use of minimally important difference of EQ-5D utility index and EQ-VAS scores in health technology assessment.
المؤلفون: Shaw C; Putnam, Portland House, New Bridge Street West, Newcastle upon Tyne, NE1 8AP, UK. caroline.shaw@putassoc.com., Longworth L; Putnam, Portland House, New Bridge Street West, Newcastle upon Tyne, NE1 8AP, UK., Bennett B; Worldwide Health Economics and Outcomes Research, Bristol-Myers Squibb Pharmaceuticals Limited, Uxbridge, UK.; Patient-Centred Outcomes, Jazz Pharmaceuticals, Oxford, UK., McEntee-Richardson L; Putnam, Portland House, New Bridge Street West, Newcastle upon Tyne, NE1 8AP, UK., Shaw JW; Worldwide Health Economics and Outcomes Research, Bristol-Myers Squibb, Lawrenceville, NJ, USA.
المصدر: Health and quality of life outcomes [Health Qual Life Outcomes] 2024 Aug 13; Vol. 22 (1), pp. 63. Date of Electronic Publication: 2024 Aug 13.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101153626 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7525 (Electronic) Linking ISSN: 14777525 NLM ISO Abbreviation: Health Qual Life Outcomes Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : BioMed Central, c2003-
مواضيع طبية MeSH: Technology Assessment, Biomedical*, Humans ; Quality of Life/psychology ; Surveys and Questionnaires/standards ; Patient Reported Outcome Measures ; Germany ; Minimal Clinically Important Difference
مستخلص: Objectives: Estimates of minimally important differences (MID) can assist interpretation of data collected using patient-reported outcomes (PRO), but variability exists in the emphasis placed on MIDs in health technology assessment (HTA) guidelines. This study aimed to identify to what extent information on the MID of a commonly used PRO, the EQ-5D, is required and utilised by selected HTA agencies.
Methods: Technology appraisal (TA) documents from HTA agencies in England, France, Germany, and the US between 2019 and 2021 were reviewed to identify documents which discussed MID of EQ-5D data as a clinical outcome assessment (COA) endpoint.
Results: Of 151 TAs utilising EQ-5D as a COA endpoint, 58 (38%) discussed MID of EQ-5D data. Discussion of MID was most frequent in Germany, in 75% (n = 12/16) of Gemeinsamer Bundesausschuss (G-BA) and 44% (n = 34/78) of Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, (IQWiG) TAs. MID was predominantly applied to the EQ-VAS (n = 50), most frequently using a threshold of > 7 or > 10 points (n = 13). G-BA and IQWiG frequently criticised MID analyses, particularly the sources of MID thresholds for the EQ-VAS, as they were perceived as being unsuitable for assessing the validity of MID.
Conclusion: MID of the EQ-5D was not frequently discussed outside of Germany, and this did not appear to negatively impact decision-making of these HTA agencies. While MID thresholds were often applied to EQ-VAS data in German TAs, analyses were frequently rejected in benefit assessments due to concerns with their validity. Companies should pre-specify analyses of continuous data in statistical analysis plans to be considered for treatment benefit assessment in Germany.
(© 2024. The Author(s).)
References: Br J Rheumatol. 1997 May;36(5):551-9. (PMID: 9189057)
Qual Life Res. 2005 Aug;14(6):1523-32. (PMID: 16110932)
Thorax. 2021 Jan;76(1):37-43. (PMID: 33023996)
Aliment Pharmacol Ther. 2009 May 1;29(9):1032-41. (PMID: 19222413)
Health Qual Life Outcomes. 2020 Oct 2;18(1):324. (PMID: 33008423)
J Clin Epidemiol. 2010 Jul;63(7):804-5; author reply 806. (PMID: 20399609)
Qual Life Res. 2021 Oct;30(10):2729-2754. (PMID: 34247326)
Lancet Oncol. 2017 Aug;18(8):1061-1075. (PMID: 28645776)
J Clin Epidemiol. 2008 Feb;61(2):102-9. (PMID: 18177782)
Bone Joint Res. 2022 Sep;11(9):619-628. (PMID: 36047008)
Qual Life Res. 2011 Dec;20(10):1727-36. (PMID: 21479777)
Expert Rev Pharmacoecon Outcomes Res. 2011 Apr;11(2):171-84. (PMID: 21476819)
Eur J Health Econ. 2020 Nov;21(8):1245-1257. (PMID: 32514643)
Thorax. 2016 Jun;71(6):493-500. (PMID: 27030578)
Mayo Clin Proc. 2002 Apr;77(4):371-83. (PMID: 11936935)
Health Qual Life Outcomes. 2006 Oct 11;4:79. (PMID: 17034633)
Health Qual Life Outcomes. 2007 Dec 21;5:70. (PMID: 18154669)
Patient. 2024 May;17(3):239-249. (PMID: 38085457)
Value Health. 2022 Sep;25(9):1463-1468. (PMID: 36049796)
Trials. 2007 Oct 25;8:31. (PMID: 17961249)
فهرسة مساهمة: Keywords: EQ-5D; Health technology assessment; Health-related quality of life; Minimally important difference
تواريخ الأحداث: Date Created: 20240812 Date Completed: 20240813 Latest Revision: 20240815
رمز التحديث: 20240815
مُعرف محوري في PubMed: PMC11321174
DOI: 10.1186/s12955-024-02272-9
PMID: 39135171
قاعدة البيانات: MEDLINE
الوصف
تدمد:1477-7525
DOI:10.1186/s12955-024-02272-9